Two protocols for switching between carvedilol, a third-generation nonselective agent with vasodilation through alpha1 blockade, and a beta1-selective agent (e.g., metoprolol, atenolol) are described.

Switching Between Beta Blockers in Heart Failure Patients: Rationale and Practical Considerations William T. Abraham, MD Disclosures CHF. 2003;9 (5) ...

For patients with heart failure, hospital participation in the IMPLEMENT-HF initiative improves adherence to quadruple ...

In this high-yield, clinically focused session, Dr. Steven L. Cohn, one of the leading experts in perioperative medicine, ...

A new understanding of how tumours exploit our nervous system is leading to new ways to treat cancer using familiar drugs ...

Two specific types of antidepressants – selective serotonin reuptake inhibitors (SSRIs) and tricyclics (TCAs) – may make ...

Combating heart failure in children and ensuring optimal pain management for cancer patients: The SNSF is providing 14.4 million Swiss francs in funding for six clinical studies as part of the IICT ...

Dapagliflozin reduced the risk of all-cause mortality or worsening heart failure by 28% in patients with aortic stenosis ...

A ccording to a new study that analyzed data from over 119 million people, deaths from heart attacks have dropped by nearly ...

Two specific types of antidepressants – selective serotonin reuptake inhibitors (SSRIs) and tricyclics (TCAs) – may make ...

A study from Stanford shows that heart attack deaths fell 89 percent from 1970-2022 while chronic heart disease deaths rose ...